This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
6 Sep 2012

Valeant to acquire Medicis for $2.6bn

Valeant Pharmaceuticals International has signed a deal to acquire dermatology specialist Medicis Pharmaceutical Corp for $2.6bn.

Valeant Pharmaceuticals International has signed a deal to acquire dermatology specialist Medicis Pharmaceutical Corp for $2.6bn.

The transaction values Medicis' common stock at $44 per share, representing a 39% premium to Medicis' closing share price on August 31, 2012.

The deal is the largest for Valeant since it was established in 2010, and follows its failed bid to buy US-based biopharmaceutical Cephalon last year for $5.7bn.

Under the agreement, the Canadian company will gain Medicis' portfolio of prescription brands, including Solodyn, an antibiotic used to treat acne; injectable filler Restylane; and acne cream Zyclara.

The pro forma net revenue for the combined company's dermatology and aesthetics businesses for 2012 is expected to exceed $1.7bn in the US.

The transaction is expected to close in the first half of 2013.

Medicis chairman and CEO Jonah Shacknai said; "Our board of directors believes this compelling all-cash transaction

Related News